The metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) is frequently over-expressed and serves as a prognostic marker in human cancers. However, little is known about the role of MALAT1 in gastric cancer. Here, we reported that the tissue and plasma MALAT1 levels were significantly higher in gastric cancer patients with distant metastasis (P<0.01) than patients without distant metastasis and the healthy controls. In addition, high levels of plasma MALAT1 independently correlated to a poor prognosis for gastric cancer patients (hazard ratio, 0.242; 95% CI, 0.154-0.836; P=0.036; Cox regression analysis). Functional studies revealed that knockdown of MALAT1 could inhibit cell proliferation, cell cycle progression, migration and invasion, and promote apoptosis in gastric cancer cells. Furthermore, the miR-122-IGF-1R signaling correlated with the dysregulated MALAT1 expression in gastric cancer. These data suggest that MALAT1 could function as an oncogene in gastric cancer, and high MALAT1 level could serve as a potential biomarker for the distant metastasis of gastric cancer.
multiple electrons and protons, and the long-lived electron-proton coupled intermediates. This is of particular importance for the gas-solid reactions involving only water and CO 2 systems. Metal-organic frameworks (MOFs) are promising photocatalysts in CO 2 reduction due to the high CO 2 adsorption, large surface areas, open and orderly pores and channels, and remarkable structural and functional designability. [6][7][8][9] Nevertheless, MOFs are typically poor electron and proton conductors owing to the low overlap between the π orbits of organic ligand and the d orbitals of metal ion, as well as lacking of sufficient proton-active sites to receive and give protons in the pores of MOFs. To enhance electron activities of MOF photocatalysts, varieties of semiconductor or metal nanoparticles are encaged into or deposited on MOFs. [10][11][12][13] In contrast, a few attentions are put on improving proton activity in the CO 2 reduction process.Keggin-type polyoxometalates (POMs) are consist of well-defined metal-oxygen clusters with reversible multiple electron redox activities. [14][15][16][17] Therefore, they generally act as an electron reservoir in composite photocatalysts to promote electron-hole separation. [18][19][20] Keggin-type POMs, being as strong Brønsted acid and having quasispherical structure with abundant exterior oxygen atoms, are incorporated into the pores of MOFs to enhance proton transfer. [21][22][23] These suggest that integrating POMs into MOF hybrids might be of great potential in the proton-coupled electron CO 2 reduction reaction. In this vein, we choose keggin-type POM, [PTi 2 W 10 O 40 ] 7− (PTiW), [24] and MOF, HKUST-1, namely Cu 3 (BTC) 2 (BTC: benzene-1,3,5-tricarboxylate), the excellent CO 2 storage material, [25,26] as promising candidates. To improve visible-light absorption, Au nanoparticles (Au NPs) are loaded in PTiW-encaged HKUST-1. For clarity, we denote the hybrid material of PTiW encaged into HKUST-1 as NENU-10 and Auloaded NENU-10 as Au@NENU-10. Compared to the unsubstituted counterpart of [PW 12 O 40 ] 3− (PW12), Ti-substituted PTiW shows higher reduction activity and protonation ability due to the more negative charges and the stronger alkaline both on terminal oxygen of TiO and bridge oxygen of TiOW (Figure 1), [27,28] which provide driving force and active protons and electrons necessary for CO 2 photoreduction. Remarkably, A key challenge for photocatalystic CO 2 reduction is the design and synthesis of photocatalyst with remarkable performance in visible-light absorption, CO 2 adsorption, and electron-coupled proton transfer. Here a visible lightdriven hybrid photocatalyst Au@NENU-10, consisting of Au nanoparticles (NPs), Ti-substituted keggin-type polyoxometalate [PTi 2 W 10 O 40 ] 7− (PTiW), and HKUST-1, is synthesized by the one-pot method at atmosphere condition where PTiW acts as both electrons' and protons' reservoir, and a reactive active center is encaged into HKUST-1 to boost CO 2 reduction, HKUST-1 as a microreactor to concentrate CO 2 molecules, and Au ...
Background:A novel coronavirus has caused an international outbreak. Currently, there are no specific therapeutic agents for coronavirus infections. Convalescent plasma (CP) therapy is a potentially effective treatment option. Methods:Patients who had recovered from COVID-19 and had been discharged from the hospital for more than two weeks were recruited. COVID-19 convalescent plasma (CCP)-specific donor screening and selection were performed based the following criteria: 1) aged 18-55 years; 2) eligible for blood donation; 3) diagnosed with COVID-19; 4) had two consecutive negative COVID-19 nasopharyngeal swab tests based on PCR (at least 24 h apart) prior to hospital discharge; 5) had been discharged from the hospital for more than 2 weeks; and 6) had no COVID-19 symptoms prior to convalescent plasma donation. In addition, preference was given to CCP donors who had a fever lasting more than 3 days or a body temperature exceeding 38.5 Celsius, and 4 weeks after the onset of symptoms. CCP collection was performed using routine plasma collection procedures via plasmapheresis. In addition to routine donor testing, the CCP donors' plasma was also tested for SARS-CoV-2 nucleic acid and S-RBD-specific IgG antibody. Results:Of the 81 potential CCP donors, 64 (79%) plasma products were collected. There were 18 female donors and 46 male donors. There were 34 first-time blood donors and 30 repeat donors. The average time between CCP collection and initial symptom onset was 49.1 days, and the average time between CCP collection and hospital discharge was 38.7 days. The average volume of CCP collected was 327.7 ml.All Alanine transaminase ( ALT ) testing results met blood donation requirements.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.